Insurance coverage for Mounjaro for sleep apnea is almost always denied, because Mounjaro is FDA-approved only for type 2 diabetes. The medication your insurer may actually pay for is Zepbound, which contains the identical active ingredient — tirzepatide — but carries a separate FDA approval, granted in December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.1U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea If your prescription is written for Mounjaro, ask your doctor whether switching the paperwork to Zepbound makes sense. Same molecule, very different answer from the insurance company.
Why the Brand Name Changes Everything
Both drugs are made by Eli Lilly. Mounjaro is approved to improve blood sugar control in type 2 diabetes.2FDA (Food and Drug Administration). Mounjaro (tirzepatide) Injection Label Zepbound carries two approvals: chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity.3FDA (Food and Drug Administration). Zepbound (tirzepatide) Injection Label
When a doctor prescribes Mounjaro for sleep apnea, the insurer sees an off-label request: a diabetes drug being used for a condition it was never approved to treat. Most plans deny off-label requests unless overwhelming evidence supports them, and the burden of proof falls on you and your prescriber. When the prescription is written for Zepbound, the insurer sees a drug being used for exactly what the FDA cleared it to do. The question shifts from whether the drug works at all to whether you meet the plan’s clinical criteria. That is a much shorter conversation.
What Insurers Require Before They Approve Zepbound
FDA approval does not mean automatic coverage. Nearly every plan requires prior authorization, meaning your doctor submits clinical documentation and the insurer decides before you pick up the prescription. The specifics differ by plan, but the thresholds cluster around the same numbers.
Clinical Thresholds
Major pharmacy benefit managers have published criteria for Zepbound approval in obstructive sleep apnea cases. Common requirements include a body mass index of at least 30 kg/m² and an apnea-hypopnea index (AHI) of 15 or more events per hour, confirmed by a sleep study, either in-lab polysomnography or a home sleep apnea test.4Prime Therapeutics. Accord Clinical Criteria Choice Weight Management An AHI of 15 corresponds to moderate sleep apnea. Mild cases scoring below that line are less likely to be approved.
CPAP Documentation
Most plans want evidence that you tried positive airway pressure (PAP) therapy first. UnitedHealthcare’s 2026 commercial policy, for example, requires documented adherence to PAP therapy — at least four hours per night on at least 70 percent of nights — with continued sleep apnea symptoms despite that adherence.5UnitedHealthcare Commercial Plan. Zepbound (tirzepatide) – Obstructive Sleep Apnea Only – Prior Authorization/Non-Formulary Patients who cannot use PAP therapy at all because of anatomy issues, mask intolerance, or other documented reasons can qualify without the trial period. If your chart does not explain why CPAP failed or was never feasible, expect that to be the first thing flagged.
The Documentation Package
Your doctor’s office needs to assemble a complete file for the prior authorization: sleep study results showing AHI, your current BMI, a record of prior treatments and their outcomes, and a letter of medical necessity. Clinical trial data strengthens the case. The SURMOUNT-OSA trials showed tirzepatide reduced AHI events by roughly 48 to 56 percent compared with placebo over 52 weeks. Incomplete documentation is the most common reason an approvable case gets denied, so confirm with your doctor’s office that the submission is thorough before it goes out.
Medicare and Medicaid
Medicare Part D plans can cover Zepbound when prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity. This falls under the standard Part D benefit.6CMS. Medicare GLP-1 Bridge Your plan’s normal formulary rules apply. If Zepbound is not on the formulary, you can request a formulary exception.
State Medicaid programs have long had the option to exclude weight-loss drugs, but that exclusion only applies to drugs prescribed for weight loss. Because obstructive sleep apnea is a distinct FDA-approved indication, Zepbound for OSA falls outside that carve-out. States in the Medicaid Drug Rebate Program are generally required to cover FDA-approved drugs for their approved uses, so Zepbound for OSA should be covered in most state Medicaid programs. Prior authorization still applies, and some states are slower than others to update their preferred drug lists after a new approval.
What You’ll Pay Without Coverage
Paying cash is steep. Mounjaro’s wholesale acquisition cost is $1,112.16 for a one-month supply of four pens, and Zepbound is priced similarly.7Lilly Pricing Info. Mounjaro Cost Information – With or Without Insurance That is before pharmacy markup.
Eli Lilly offers a savings program that can bring Zepbound down to as little as $25 for up to a three-month supply for commercially insured patients whose plan covers the drug.8Zepbound. Savings Options – Zepbound (tirzepatide) Savings options also exist for patients without insurance or whose plan does not cover Zepbound, though the discount is smaller. The Lilly Cares Foundation Patient Assistance Program separately provides certain Lilly medications at no cost to qualifying individuals based on income and lack of coverage; your prescriber can help you apply.
One route that is no longer open: compounded tirzepatide. The FDA ended the shortage window in March 2025, so compounded versions are not a legal alternative.
If Your Claim Is Denied
Denials happen even when the medical case is strong. The Explanation of Benefits will tell you why. Common reasons include missing prior authorization, incomplete documentation, or a finding that the treatment is not medically necessary under the plan’s criteria. That explanation is your roadmap.
Peer-to-Peer Review
Before filing a formal appeal, your doctor can often request a peer-to-peer conversation with the insurer’s medical reviewer. It is a direct phone call where your doctor explains why you need the medication. These calls can resolve denials quickly when the issue was a documentation gap or a misunderstanding of your clinical situation.
Internal Appeal
If you have an employer-sponsored health plan governed by federal law, you have at least 180 days from the date of denial to file an internal appeal. The appeal cannot be reviewed by the same person who issued the denial, and if the denial involved a medical judgment, the reviewer must consult a health care professional with relevant training who was not part of the original decision. You are entitled to free copies of all documents the insurer relied on, which helps you see exactly what evidence was found insufficient. For post-service claims, the insurer must decide within 60 days of receiving your appeal, or 30 days per level if the plan has two appeal stages.9eCFR. Claims Procedure
Your appeal should include everything from the original prior authorization plus whatever was missing. A strong letter of medical necessity referencing your sleep study results, BMI, PAP therapy history, and the SURMOUNT-OSA trial data can be decisive. If the denial cited specific clinical criteria, ask the insurer to provide them so your doctor can address each point.
External Review
If internal appeals fail, federal law requires most non-grandfathered health plans to offer an external review by an independent third party.10eCFR. 45 CFR 147.136 – Internal Claims and Appeals and External Review Processes Some states run their own external review programs; where none qualifies, a federal process fills the gap. Reviews are decided by medical professionals with no ties to your insurer, and the decisions are generally binding. Filing fees, where they exist, are typically $25 or less. Expedited external reviews are available for urgent medical situations, with decisions issued in days rather than weeks.
State Insurance Department Complaints
Every state has an insurance department that oversees how insurers handle claims. Filing a complaint will not force an approval, but it triggers an investigation into whether the denial violated state regulations or the terms of your policy. If a violation is found, the insurer may be required to reconsider. Complaints are free and do not require a lawyer.
How to Improve Your Odds From the Start
Approved patients tend to do the same few things right. Make sure the prescription is written for Zepbound, not Mounjaro. That alone removes the off-label hurdle. Get a current sleep study on file showing your AHI; insurers will not accept old results. If you have been prescribed CPAP, document your usage carefully. Modern CPAP machines track hours automatically, and that data drops directly into the prior authorization. If CPAP has not worked despite consistent use, that compliance record becomes your strongest piece of evidence.
Have your doctor prepare the letter of medical necessity before the prior authorization is submitted, not after a denial. Include everything the insurer’s published criteria ask for: BMI, AHI, PAP history, and the clinical reasoning for this medication as the next step. A complete file up front is far more effective than supplementing an appeal later.